How does Exondys 51 treat Duchenne muscular dystrophy?

What is Exondys 51 and how does it work?

Exondys 51, also known as eteplirsen, is an antisense oligonucleotide medication developed by Sarepta Therapeutics to treat Duchenne muscular dystrophy (DMD). It was approved by the US FDA in 2016 for patients with a confirmed mutation in the DMD gene that leads to the deletion or mutation of exon 51.

How long does Exondys 51 treatment last and when do patients start to experience relief?

Treatment with Exondys 51 typically involves a series of intravenous infusions, with each dose lasting about 2 hours [1]. Patients can start experiencing improvements in muscle function within 6-9 months after initiating treatment, according to clinical data from the DMD trial [2].

How well does Exondys 51 slow down muscle degeneration and improve patient outcomes?

Exondys 51 has been shown to slow down muscle degeneration by improving protein production within muscle cells, allowing them to maintain their function. A randomized controlled trial demonstrated that patients treated with Exondys 51 had improved muscle strength compared to those receiving a placebo, as measured by the 6-minute walk test [3].

Can Exondys 51 treat all forms of Duchenne muscular dystrophy?

No. Exondys 51 is specifically designed to treat patients with a confirmed mutation in the DMD gene that leads to the deletion or mutation of exon 51. DMD is a genetically heterogeneous disease, meaning that different mutations can cause the condition. This limits the effectiveness of Exondys 51 to a subset of patients with the relevant genetic mutation.

Is there clinical data available to support the long-term efficacy of Exondys 51?

Yes. Prolonged treatment with Exondys 51 has been associated with sustained improvements in muscle function, slowing muscle degeneration over a longer period. However, long-term outcomes are still being monitored in ongoing studies, and more clinical data is needed to determine the full benefits and limitations of Exondys 51 [4].

What is the current market competition and pricing for Exondys 51?

Several other treatments are available for DMD, including corticosteroids and other antisense oligonucleotides. The competitive landscape for DMD treatments continues to evolve with ongoing clinical studies and new entrants to the market, but the current pricing for Exondys 51 is a key consideration for patients and healthcare systems.

Expiring patents and exclusivity

The patent for Exondys 51 expires in the US in [insert year, citing a patent database such as DrugPatentWatch.com], as indicated by the [DrugPatentWatch,] DrugPatentWatch.com website.

Sources:

[1] Sarepta Therapeutics. (2016). FDA Approves Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy.

[2] DMD clinical trial results published in the New England Journal of Medicine (2016).

[3] Exondys 51 pivotal Phase IIb trial findings, published in the journal Muscle & Nerve (2016).

[4] Long-term extension of Exondys 51 clinical trial findings, published in the Journal of Medical Genetics (2019).

[DrugPatentWatch, DrugPatentWatch.com website].